Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | FURIN | P09958 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20616683 | 1.00 | SIRT5 (0.38) | SIRT5MAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL25826704 | 0.94 | SIRT2 (0.37) | SIRT5MAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL19387330 | 0.93 | SIRT5 (0.38) | SIRT5MAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL25826705 | 0.93 | FURIN (0.37) | SIRT5MAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL25615822 | 0.91 | SIRT5 (0.41) | SIRT5SIRT2SIRT1SIRT3FURIN | |
| SCHEMBL27278172 | 0.91 | SIRT5 (0.39) | SIRT5MAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL26254328 | 0.91 | MAP1LC3B (0.37) | SIRT5MAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL25830938 | 0.90 | SIRT2 (0.42) | SIRT5SIRT2SIRT1SIRT3FAP | |
| SCHEMBL26254329 | 0.90 | SIRT2 (0.36) | SIRT5MAP1LC3BSIRT2SIRT1SIRT3 | |
| SCHEMBL18823533 | 0.90 | CHRNA1 (0.38) | SIRT5MAP1LC3BSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065340-B2 | Polyoxazoline antibody drug conjugates | SERINA THERAPEUTICS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190000985-A1 | Polyoxazoline Anitbody Drug Conjugates | SERINA THERAPEUTICS (AL), INC. | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11065340-B2 | Polyoxazoline antibody drug conjugates | FCGR2A, FCGR3B, FCGR1A | SIRT5 1997/4885MAP1LC3B 3219/4885SIRT2 3531/4885 |
| US-20190000985-A1 | Polyoxazoline Anitbody Drug Conjugates | CD79B, ANTXR2, FCGR2A | SIRT5 3249/4885MAP1LC3B 2756/4885SIRT2 4052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.